Bioventix Plc · LSE:BVXP
Bioventix — Investor Presentation (March 2022)
11 slides from Bioventix's investor presentation, Mar 28, 2022
Slide 1: Bioventix plc
Bioventix plc 28 March 2022 04 Bioventix
Slide 2: Antibodies and Blood Testing
2 Antibodies and Blood Testing ▪Bioventix creates and manufactures sheep monoclonal antibodies (SMAs). Customers incorporate these antibodies in reagent packs for use on automated blood-testing machines antigen antibody ▪Superior antibodies can facilitate improved tests ▪Bioventix sells liquid “phys
Slide 3: Diagnostic Applications for SMAs
3 Diagnostic Applications for SMAs Vitamin D Thyroid function Fertility Chest pain; heart attack Drug testing (25-OH vitamin D) (thyroxine, T3) (testo, estrogens) (troponin) (THC) ▪Bioventix has a portfolio of ~20 antibodies that are sold globally to in vitro diagnostics (IVD) companies ▪Most have b
Slide 4: Antibodies and Business Dynamics
4 Antibodies and Business Dynamics ▪Projects can be internally driven or sponsored by customers +1 year Prototype test Old test 2-4 years ▪Bioventix takes about 1 year to create new antibodies = 3-5 years total ▪Even for established diagnostics, customers take 2-4 years to prototype tests, conduct f
Slide 5: Key Interim Financials
5 Key Interim Financials £ (‘000) Year to ½ year to ½ year to Finncap 30.6.21 30.12.20 30.12.21 forecast 2021/22 Sales 10,930 5,165 4,731 10,400 (-8.4%) P/(L) before tax 8,118 3,718 3,562 8,000 (-4.2%) (adjusted) P/(L) after tax 6,731 3,098 2,988 6,700 (-3.6%) (adjusted) Period-end cash 6,495 5,844
Slide 6: Sales Commentary
6 Sales Commentary ▪ Many core revenue streams have continued to be flat over the last ½ year • The coronavirus pandemic has continued to impact sales • vitamin D sales have experienced reduced growth, particularly with “antibody hungry” formats (ie assays with a higher mass of antibody used per tes
Slide 7: Pipeline Development Commentary
7 Pipeline Development Commentary ▪ Secretoneurin (CardiNor/cardiac): work continues at our collaborators in Oslo to define the potential utility of secretoneurin in cardiac diagnostics. We anticipate more data during 2022 ▪ Amyloid (Pre-Diagnostics/Alzheimers): Development of two new assays continu
Slide 8: Bioventix Lab, Farnham
8 Bioventix Lab, Farnham ▪ Technology development ▪ Purification and assay ▪ Cell culture ▪ Bioreactor production ▪Supply chain issues experienced during 2021 have continued into 2022 but have been adequately managed to date
Slide 9: Significant Shareholders
9 Significant Shareholders Institution Shares % (1000s) Sanford DeLand 1,040 20.0 Liontrust 587 11.3 Peter Harrison 417 8.0 Total shares = 5,209,333 (Mar Hargreaves Lansdown Stockbrokers 350 6.7 2022) Gresham House 260 5.0 Schroder Investment Management 215 4.1 Danske Bank 166 3.2 ▪From permissions,
Slide 10: Bioventix Directors
10 Bioventix Directors ▪Peter Harrison, CEO ▪Ian Nicholson, Chairman ▪>30 years experience of ▪>30 years experience of antibody technology at commercial development within Celltech, KS Biomedix & biotechnology including Bioventix Amersham, Celltech, Chroma, Clinigen, Consort Medical & F2G ▪Peter rem
Slide 11: Conclusions and Outlook
11 Conclusions and Outlook ▪ There have been challenges over the last two years but we continue to have confidence in the strength of our core business and the outlook for the full year ▪ The continued growth of troponin revenues has helped mitigate against the loss of NT-proBNP revenues ▪ Research